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Background
Targeting Dendritic Cells (DCs) with anti-DC receptor
antibody-antigen fusion proteins represents a novel
approach to vaccine development. In mouse models,
these innovative vaccines induce enhanced cellular,
humoral, or mixed immune responses. Targeting antigens
to particular DC subsets can lead to distinct immune out-
comes but the consequence of targeting antigen via differ-
ent receptors on the same DC is not well-studied.
Methods
We developed recombinant mAbs (rAbs) for multiple
internalizing human DC receptors and engineered them
fused via the heavy chain C-terminus to a string of five 19-
to 32-amino-acid long sequences from HIV-1 Gag, Nef
and Pol proteins (rAb.HIV5pep). These peptides bear
multiple highly conserved CD4+ and CD8+ T cell
epitopes. Anti-DCIR, anti-LOX-1, anti-CD40, and a con-
trol IgG4.HIV5pep fusion proteins were incubated with
HIV patient PBMCs or DC-T cell co-cultures and after 10
days the total T cells were stimulated with each individual
HIV peptide, and then antigen-specific cytokine produc-
tion was detected using intracellular staining and multi-
plex bead assay from culture supernatants.
Results
At low doses (10 – 0.01 nM) all three DC-targeting
HIV5pep vaccines, but not the control IgG4.HIV5pep,
elicited expansion of antigen-specific T cells. The range of
antigen-specific T cells recall responses over the 5 HIV
peptide regions varied for each patient, but in sum
epitopes from all 5 regions could be effectively processed
and presented. All three DC-targeting vaccines expanded
antigen-specific T cells, but anti-CD40.HIV5pep was strik-
ingly more effective for eliciting multi-epitope CD4+ and
CD8+ T cell responses. The expanded antigen-specific T
cells were polyfunctional since the CD4+ T cells produced
multiple cytokines, while the CD8+ T cells produced
cytokines and had CTL characteristics (perforin, granzyme
B, surface CD107a, proliferation capacity).
Conclusion
Our in vitro data justify preclinical studies with anti-
CD40.HIV5pep in non-human primates for priming
naive T cells with a broad range of epitopes and potent
effector functions.
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